Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.64 |
| ▸ | BCL2 | P10415 | 9/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370557 | 0.89 | CTSL (0.81) | CTSLBCL2HDAC8ITGB3ITGA2B | |
| SCHEMBL12371616 | 0.88 | CTSL (0.57) | CTSLBCL2CYP1A2CYP2C19CTSS | |
| SCHEMBL13620289 | 0.81 | CTSL (0.59) | CTSLBCL2HDAC8ITGB3ITGA2B | |
| SCHEMBL12372028 | 0.79 | CTSL (0.55) | CTSLBCL2HDAC8ITGB3ITGA2B | |
| SCHEMBL12371564 | 0.76 | CTSL (0.73) | CTSLL3MBTL1CTSSCTSK | |
| SCHEMBL12370596 | 0.76 | CTSL (0.73) | CTSLL3MBTL1CTSSCTSK | |
| SCHEMBL12371562 | 0.75 | CTSL (0.50) | CTSLBCL2HDAC8ITGB3ITGA2B | |
| SCHEMBL12372026 | 0.75 | CTSL (0.60) | CTSLBCL2HDAC8ITGB3ITGA2B | |
| SCHEMBL12371614 | 0.74 | CTSL (0.67) | CTSLBCL2ITGB3ITGA2BCTSK | |
| SCHEMBL12371565 | 0.73 | CTSL (0.50) | CTSLBCL2HDAC8ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-25 | — | — | US | disclosed |
| WO-2009136997-A2 | INHIBITORS OF HUMAN CATHEPSIN L, CATHEPSIN B, AND CATHEPSIN S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | CTSB, CTSS, CTSV | CTSL 7/4885BCL2 584/4885MCL1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.